4263 — Susmed Income Statement
0.000.00%
Last trade - 00:00- ¥9bn
- ¥4bn
- ¥531m
- 68
- 10
- 16
- 18
Annual income statement for Susmed, fiscal year end - June 30th, JPY millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 34.9 | 115 | 317 | 531 |
| Cost of Revenue | ||||
| Gross Profit | 33.3 | 106 | 306 | 523 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 203 | 454 | 562 | 584 |
| Operating Profit | -169 | -338 | -245 | -53.5 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -96.6 | -276 | -233 | -49.5 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -96.9 | -278 | -233 | -50.7 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -96.9 | -278 | -233 | -50.7 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -96.9 | -278 | -233 | -50.7 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -5.91 | -17.7 | -13.8 | -2.89 |
| Dividends per Share |